Overview
Efficacy and Safety of Topical Nicotinamide in Treatment of Discoid Lupus Erythematosus
Status:
Recruiting
Recruiting
Trial end date:
2022-09-30
2022-09-30
Target enrollment:
0
0
Participant gender:
All
All
Summary
Cutaneous lupus erythematosus (CLE) is lupus affecting the skin. In this autoimmune disease, the body's immune system attacks healthy skin. There are 3 main types: Acute cutaneous lupus, Subacute cutaneous lupus, and Chronic cutaneous lupus ("discoid lupus"). Lupus most often appears between the ages of 20 and 50 years; it affects women more than men, and it may happen more in patients with a family history of lupus or other autoimmune diseases.Phase:
N/AAccepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Al-Azhar UniversityTreatments:
Niacin
Niacinamide
Nicotinic Acids
Criteria
Inclusion Criteria:- Age: between 18 years and 65 years old
- Patients clinically and histopathologically newly diagnosed as DLE
- Patients clinically and histopathologically diagnosed with cutaneous lupus
erythematosus that has not responded to treatment with
hydroxychloroquine(200-400mg/day) plus corticosteroid at a dosage less than the
equivalent of (0.5mg/kg/day) for the preceding two months or a longer period
Exclusion Criteria:
- Age < 18 years old
- Pregnant and lactating women
- A history of treatments with multivitamins in the recent month
- Soft tissue infection
- Severe comorbidities including heart failure, respiratory failure
- Acute severe infections such as cellulitis or a history of HBV or HCV